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Objectives: In patients with burns an early accurate diagnosis of burn depth is 
essential to determine optimal treatment. The combination of Laser Doppler imaging 
(LDI) and clinical assessment leads to an accurate estimate of burn depth. However, 
the actual effects of the introduction of LDI on therapeutic decisions, clinical out-
comes and costs are unknown. The aim of our study was to analyse the effectiveness 
and cost-effectiveness of LDI in burn care. The effects of LDI on decision-making, 
clinical outcomes, costs, and cost-effectiveness were assessed. MethOds: A ran-
domised controlled trial was conducted in all three Dutch burn centres, includ-
ing subsequent patients with burns of indeterminate depth. In the standard care 
(SC) group, burn depth and treatment choices were based on clinical assessment 
only, in the other group (LDI) clinical assessment and LDI results were combined. 
Primary outcome was the effect of the introduction of LDI on wound healing time. 
The economic evaluation was performed from a societal perspective with a bottom 
up approach, following the micro-costing method. Results: Mean time to wound 
healing from randomisation was 14.3 days in the LDI group and 15.5 days in the SC 
group (p= 0.258). In the subgroup of clinical patients requiring surgery earlier deci-
sion for surgery and a shorter wound healing time were observed in the LDI group 
(16.0 versus 19.9 days, p= 0.029). Mean total costs per patient were € 18 549 versus 
€ 18 896 (p= 0.837). cOnclusiOns: LDI proved to provide guidance for therapeutic 
decisions with a significantly shorter wound healing time in the subgroup of clinical 
patients requiring surgery. When time to surgery can be reduced by 2.4 days, similar 
to the time to decision for surgery in our study, cost savings of € 794 per scanned 
patient can be achieved.
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Objectives: Actinic Keratosis (AK) is the most common neoplastic lesion of the 
skin, its prevalence in Italy is 1.4% in the adult population, over the age of 45 
years. The objective of this study is to evaluate through the development of a 
decision-tree model, the impact in terms of cost-effectiveness of treatment of 
patients with actinic keratosis (on the face), of ingenolo mebutato gel vs. imiqui-
mod cream. MethOds: The effectiveness was expressed in terms of utility; the 
ratio of cost effectiveness was expressed in terms of cost per Quality Adjusted Life 
Years (QALYs). The time horizon of the simulation was 12 months. For ingenolo 
mebutato was considered the price to the public starting from the ex-factory price 
currently lower in Europe (Spain price), while for imiquimod has been adopted 
the reference price, because of the drug generication. It was also considered the 
adherence rate of patients to the two treatment alternatives, due to the different 
duration of treatment (2-3 days Vs. 4-8 weeks) and adverse events, which in the 
case of imiquimod may persist for all the therapy lenght. Results: Based on 
these assumptions, ingenolo mebutato therapy is found to be less expensive and 
more effective, and so dominant, compared to imiquimod. The cost-effectiveness 
analysis has been tested with univariate sensitivity analysis, which confirmed 
the validity of the base case. cOnclusiOns: Based on these statement, it seems 
clear that ingenolo mebutato, due to its way of administration combined with its 
expected cost, represents a rational investment for the treatment of AK in the 
landscape of our national health system.
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Objectives: The national immunization program (NIP) on a voluntary basis 
started in 2010 in Croatia, including the 10-valent PCV10 and the 13-valent PCV13. 
We compare the cost-effectiveness of PCV10 and PCV13 use in the NIP. MethOds: 
A Markov model was developed to examine cost-effectiveness of PCV13 versus 
PCV10 from the payer’s perspective in 10 years. The simulated diseases were inva-
sive pneumococcal disease (bacteremia and meningitis), all-cause community 
acquired pneumonia (CAP), and all-cause acute otitis media (AOM). Direct effec-
tiveness was extrapolated from PCV7 clinical trials, adjusted by local serotype. 
Indirect effect (IE) was extrapolated from the US surveillance data following uni-
versal PCV7 use. Vaccine prices per dose for PCV10 and PCV13 were € 45.16 and 
€ 47.71, respectively. The epidemiology inputs were based on national sources or 
adopted from neighboring Slovenia. Costs were obtained from local reimburse-
ment lists and the DRG system. The IE for PCV10 was separately taken at 0%, 
50% and 100% level. Results: Compared to PCV10 with presumed no IE, PCV13 
could avoid additional 985 IPD cases, 15583 cases of inpatient and 26481 cases of 
outpatient CAP, and 53555 AOM cases, whereas for modeled 50% IE of PCV10 only 
679,10568,17 641 and 35026 cases would be avoided, and for modeled 100% IE of 
PCV10 372,5552,8798,16498 cases would be avoided, respectively. There would be 
2778 or 1958 or, 1137 deaths avoided, respectively. PCV13 compared to PCV10 with 
assumed no IE leads to € 3.060 million more spent on vaccination and € 28.585 mil-
lion saved, giving thus overall saving € 25.524 million in 10 years. cOnclusiOns: 
The cost-effectiveness analysis showed PCV10 to be dominated by PCV13 by its 
overall lower costs and higher number of QALY as well as LYG gained, regard-
less of the IE level. The results were most sensitive to the cost and incidence of 
hospitalized pneumonia.
characteristics were obtained from WHO estimates or local sources, adjusted to 
local conditions. PCV13 direct and indirect effectiveness was extrapolated from 
PCV7 trials and surveillance records, adjusted to local serotype distribution. Cost 
of vaccine was USD 16.34. A discount rate for cost and life-years was 3%. The payer 
and societal perspectives were considered. Results: The budget impact in a sin-
gle year with PCV13-based NIP in place would amount to USD 1.82 million, or USD 
7.93 million without indirect vaccine protection considered. From this investment, 
141 971 illnesses (1071 IPDs, 12477 CAPs and 128423 OMs) and 347 deaths could be 
avoided annually. Without indirect vaccine protection, 58 524 illnesses (601 IPD, 4721 
CAP, 53202 OM) and 184 deaths could be avoided. The cost-effectiveness analysis 
produced ICER of USD 340/LYG or USD 367/QALY from the payer’s perspective. From 
the societal perspective, the NIP is dominant. Not considering indirect protection, 
the ICER would be USD 140/LYG or USD 152/QALY from a societal perspective and 
USD 1157/LYG or USD 1254/QALY from a payer perspective. cOnclusiOns: PCV13-
based NIP delivers benefits and cost savings that greatly offset the investment into 
vaccine. WHO strongly encourages investment in interventions that deliver an addi-
tional year of life in full quality for less than one GDP per capita (USD 4237); hence, 
a PCV13-based NIP with the above ICER presents an attractive option.
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Objectives: Ranibizumab has demonstrated efficacy in patients with myopic 
choroidal neovascularization (mCNV) and is the first anti-VEGF licensed in this 
indication. Aflibercept is being evaluated for use in mCNV. An existing model dem-
onstrating the cost-effectiveness of ranibizumab versus verteporfin photodynamic 
therapy was adapted to provide an initial evaluation of ranibizumab versus afliber-
cept. MethOds: A Markov model in mCNV with a lifetime horizon and visual acuity 
health states was adapted to evaluate the cost-effectiveness of ranibizumab and 
aflibercept from a UK health care perspective. Baseline characteristics, injection 
frequency and ranibizumab efficacy were based on the disease activity treatment 
arm from the RADIANCE study (n= 116, Caucasian, Indian and East Asian patients). 
Data for aflibercept were derived from initial results for the aflibercept treatment 
arm from the MYRROR study (n= 90, East Asian patients only). Relative efficacy 
was assessed by indirect comparison. An evaluation using the East Asian subgroup 
of the ranibizumab disease activity treatment arm in RADIANCE (n= 35) was also 
conducted. Results: Ranibizumab dominated aflibercept in both evaluations. 
Based on the disease activity arm from RADIANCE, ranibizumab was associated 
with a lower lifetime cost (incremental cost -£1770) and higher lifetime quality-
adjusted life-years (QALYs) (incremental gain 0.02) than aflibercept. Results were 
similar for the evaluation based on the East Asian subgroup. Ranibizumab was 
associated with a lower lifetime cost (incremental cost -£2856) and higher lifetime 
QALYs (incremental gain 0.06) than aflibercept. These results were driven by the 
greater number of injections, higher treatment and recurrence costs, and smaller 
proportion of patients gaining ≥ 20 letters visual acuity for aflibercept compared 
with ranibizumab. cOnclusiOns: This initial analysis suggests that ranibizumab 
is less costly and is associated with a gain in QALYs relative to aflibercept based on 
the disease activity arm and the East Asian subgroup from RADIANCE, as well as 
initial data from MYRROR.
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Objectives: Central retinal vein occlusion (CRVO) is caused by a blood clot in the 
central retinal vein, which slows or stops blood from leaving the retina. As a result, 
blood and fluids can accumulate, causing retinal injury and vision loss. Thus, a 
major complication in eyes with CRVO is macular oedema (ME) and is the primary 
factor for poor visual acuity and visual fields in non-ischemic CRVO. A global cost-
effectiveness model was developed and adopted to estimate effects and associ-
ated costs, in Sweden, for treatment of ME secondary to CRVO with aflibercept 
compared to ranibizumab. MethOds: A Markov model was developed, including 
health states that reflect the clinical treatment and disease progression/regression 
of the ME. The simulated patient population consisted of adults treated for ME 
secondary to CRVO with an average starting-age of 64 years. Patients were treated 
and monitored for two years and followed for 15 years in the base case. Treatment 
regimens were taken from clinical trials with aflibercept (GALILEO & COPERNICUS) 
and ranibizumab (CRUISE & HORIZON), with 8.2 vs. 8.8 injections the first year and 
2.9 vs. 3.5 injections the second year, respectively. Results: Aflibercept can be 
regarded as a cost-effective, i. e. dominating, treatment-alternative compared to 
ranibizumab as aflibercept is both less costly (total incremental cost of more than 
-35,000 SEK) and more effective (total incremental QALYs of 0.061) than ranibi-
zumab. Due to the more treatments, ranibizumab had higher drug (incremental 
cost: -8,537 SEK) and administration (incremental cost: -5,793 SEK) costs compared 
to aflibercept. Probabilistic sensitivity analysis showed that aflibercept was domi-
nating over ranibizumab in 70% of the simulations. cOnclusiOns: Aflibercept 
is more cost-effective than ranibizumab for the treatment of ME secondary to 
CRVO in Sweden.
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probabilistic sensitivity analysis suggests that at willingness-to-pay threshold of 
£20-£30,000 per quality-adjusted life year, the probability of early treatment being 
cost-effective is 60%. cOnclusiOns: Panretinal photocoagulation administered 
at the severe NPDR stage is likely to be cost-effective. However, given the limita-
tions of the evidence on current treatments, these results to be interpreted with 
caution. A trial of early versus deferred laser therapy is needed to provide better 
data based on modern treatments.
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trEAtMEntS in finlAnd
Soini E.1, Hallinen T.1, Sokka A.L.2, Saarinen K.3
1ESiOR Oy, Kuopio, Finland, 2LEO Pharma Oy, Vantaa, Finland, 3PlusTerveys Oy, Nastola, Finland
Objectives: CUA of cryosurgery, topical treatments (diclofenac 3% 12 weeks, 
imiquimod 3.75% 6 weeks or 5% 4/8 weeks, ingenol mebutate gel (IMG) 0.015%/
head 3 days or 0.05%/body 2 days), and methyl aminolevulinate + photodynamic 
therapy (MAL+PDT) in the treatment of 25cm2 AK-plague affecting any body 
part. MethOds: A sequential probabilistic decision-tree with 2-year time-horizon 
was used to assess the cost-utility (incremental cost-effectiveness ratio, ICER) of 
AK-treatments, and to determine the cost-effectiveness acceptability frontier (CEAF) 
and expected value of perfect information per patient (EVPI) from health care payer 
perspective. In the model, the first-line AK-treatment resulted in complete clearance 
(CC) with or without adverse events (AE), non-CC or AK-recurrence. Non-CC AK was 
retreated with PDT and AK-recurrence was retreated with the previous treatment. 
Incident AK-patients (year 2009, n= 3409, organ transplant patients excluded) were 
identified from the Finnish hospital discharge register to assess AK-related 2-year 
secondary health care costs for patients initiating different treatment regimens. 
Other costs included general practitioner, AE-management, and outpatient drugs 
(5/2014 without VAT; other costs in 2013 value). Quality-adjusted life-years (QALY) 
were based on EQ-5D. Results were discounted with 3% annually. Results: The 
mean per patient 2-year QALYs (costs) were 1.519 (€ 727) for IMG 0.015%, 1.518 (€ 887) 
for MAL+PDT, 1.516 (€ 802) for IMG 0.05%, 1.514 (€ 995) for diclofenac, 1.512 (€ 815) for 
imiquimod 3.75%, 1.511 (€ 707) for imiquimod 5%, and 1.507 (€ 1010) for cryosurgery. 
IMG 0.015% had € 2806/QALY gained ICER against imiquimod 5%, and dominated 
other AK-treatments. IMG 0.05% dominated diclofenac, imiquimod 3.75% and 
cryosurgery, and had € 21,550/QALY gained ICER against imiquimod 5%. MAL+PDT 
had € 32,848/QALY gained ICER against IMG 0.05%. Based on the CEAF, IMG 0.015% 
was the optimal treatment when willingness-to-pay/QALY gained exceeded € 2806. 
The EVPI was € 25/€ 81/€ 211 with the willingness-to-pay of € 0/€ 15,000/€ 30,000 per 
QALY gained. cOnclusiOns: IMG 0.015% was the most cost-effective first-line 
AK-treatment.
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Objectives: To estimate the cost-effectiveness of ranibizumab 0.5mg pro re nata 
(PRN) compared with aflibercept 2mg bi-monthly in the treatment of visual impair-
ment (VI) due to diabetic macular oedema (DMO) taking a UK health care perspec-
tive. MethOds: A Markov model previously reviewed by the National Institute for 
Health and Care Excellence (NICE) was used to simulate the long-term outcomes 
and costs (at 2012 price level) of treating DMO. The health states were defined by 
increments of 10 letters in best-corrected visual acuity (BCVA) with a 3-month 
cycle length. Patients could gain (or lose), at most, 2 health states between two 
cycles. A lifetime time horizon was implemented. Future costs and health out-
comes were discounted at 3.5% per annum. Baseline characteristics, ranibizumab 
effectiveness and adverse events were estimated with data from the RESTORE trial 
(36 months). A published network meta-analysis was used to assess the relative 
effectiveness of ranibizumab to aflibercept. Aflibercept injection frequency was 
calculated with VIVID/VISTA phase III trials. Different utilities were used if the 
treated eye was the better or the worse-seeing eye. Results: Ranibizumab mono-
therapy leads to an incremental gain of 0.05 quality-adjusted life-years (QALY) 
(0.04 from the better-seeing eye and 0.01 from the worse-seeing eye) with a cost 
savings of ₤5,841 relative to aflibercept. Therefore, ranibizumab provides greater 
health gains with lower overall costs than aflibercept. Probabilistic sensitivity 
analysis shows that ranibizumab has a 58% probability of being dominant and 
79% probability of being cost effective compared with aflibercept at a willingness-
to-pay threshold of £20 000/QALY. cOnclusiOns: Ranibizumab is dominant over 
aflibercept in the treatment of VI due to DMO.
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Objectives: The next generation of artificial vision devices (AVDs), which is cur-
rently tested in clinical trials, has the potential to improve the vision of blind 
patients with retinitis pigmentosa (RP) in a manner that they will be categorized 
as visual impaired but no longer as blind. This unprecedented vision improvement 
will result in a mentionable quality of life gain which poses the question at which 
costs the next generation AVDs are to be regarded as cost-effective. MethOds: 
In order to answer this research question a Markov model, with the health states 
blind, visual impaired and death, was developed to simulate and to compare 
the costs and effects of next generation AVDs versus best supportive care (BSC) 
over a lifetime horizon. Health care costs and health utilities for the Markov health 
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Objectives: To compare ranibizumab with photodynamic therapy (PDT) for 
the treatment of predominantly classic chorodial neovascularization associated 
with age-related macular degeneration (AMD) by means of cost-utility analysis in 
China. MethOds: This study compared cost-effectiveness between Ranibizumab 
group (each delivering 0.5 mg of ranibizuamb monthly) and PDT group for the first 
year (short-term) using decision tree model, from third-payer perspective. During 
a 10-year time horizon (long-term), a Markov model was constructed to extrapolate 
effects of treatment beyond clinical trials from a societal perspective (discounted at 
5%). Visual acuity data from the Anti-Vascular Endothelial Growth Factor Antibody 
for the Treatment of Predominantly Classic Choroidal Neovascularization in AMD 
(ANCHOR) trial were applied. Direct-vision-related medical costs were based on 
Clinical Pathway of AMD in China and experts consultation. We performed a lit-
erature review and meta-analysis to estimate the costs related to comorbid states, 
including fall and depression resulting from low vision after suffer from AMD, which 
were rarely inclusive in most previous studies. Informal care costs and utilities data 
were derived from published studies. All costs were adjusted according to 2012 price 
index in China. Probabilistic sensitivity analyses (PSA) were performed to test the 
robustness in structural assumptions and parameter inputs. Cost-effective accepta-
bility curves were performed after a 1000-sample Monte Carlo simulation. Results: 
In short-term model, the incremental cost-effectiveness ratio (ICER) was $81,029/
QALY for ranibizumab compared with PDT. The ICER was reduced to $13,206/QALY 
for a 10-year time frame, when follow-up costs were included. From a societal per-
spective, PSA revealed a 97.75% probability of ranibizuamb being more cost-effective 
than PDT at a threshold of $18,278 per QALY gained (3 times Chinese GDP per capita 
in 2012) in China. cOnclusiOns: Ranibizumab can be a long-term cost-effective 
option for the treatment of AMD compared with PDT from a societal perspective.
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Objectives: To conduct the cost-utility analysis (CUA) of treatment strategy with 
ranibizumab recommended by the Chinese Clinical Pathway of age-related macu-
lar degeneration (AMD) in China. MethOds: Visual acuity data for the as-needed 
dosing regimen with ranibizumab (RBZ-PRN, administrated every month for three 
doses, additional reinjections were determined by physicians’ need) were derived 
from pivotal trials, based on ranibizumab dose of 0.5 mg. Decision tree model and 
Markov model were developed to estimate RBZ-PRN compared with best supportive 
care (BSC) for short and long term. The first year decision tree model from a third-
payer perspective was performed to estimate CUA in short-term. Then a 10-year 
Markov model from a societal perspective were constructed (discounted at 5%) in 
long-term CUA estimation. Resource utilization was obtained from official recom-
mendations in China. The costs of low-vision related disease were extrapolated from 
meta-analysis. Informal care costs and utility values were estimated by published 
studies. The uncertainty was identified in a one-way sensitivity analysis and proba-
bilistic sensitivity analysis (PSA). Cost-effective acceptability curves were obtained 
by a Monte Carlo approach with 1000 repetitions. Results: For RBZ-PRN compared 
with BSC, the incremental cost-effectiveness ratios (ICER) ranged from $90,546/QALY 
for the 1-year time frame to $9,787/QALY for the 10-year time horizon. As indicated 
in the PSA, RBZ-PRN was the optimal strategy in 100% of cases below the willingness 
to pay threshold of $18,278 per QALY gained (3 times Chinese GDP per capita in 2012) 
for the 10-year model. cOnclusiOns: When administered as needed, ranibizumab 
is cost-effective compared with BSC from a societal perspective. In China’s current 
clinical practice, this can be a useful tip for decision-makers who should consider 
cost-effective issues for the treatment of wet-AMD.
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Objectives: Diabetic retinopathy (DR) is a leading cause of sight loss in people 
of working age. There have been recent developments in laser photocoagulation 
techniques, along with anti-vascular endothelial growth factor drugs for the 
treatment of severe non-proliferative and proliferative DR. The aim of the study 
was to evaluate the cost-effectiveness of panretinal photocoagulation admin-
istered at the severe non-proliferative diabetic retinopathy (NPDR) stage (early 
treatment), compared with waiting until high-risk proliferative (HR-PDR) char-
acteristics (deferred treatment) developed. MethOds: A Markov model with a 
30-year time horizon was developed, with clinical pathway options for patients 
presenting with moderate NPDR through to irreversible-severe vision loss and 
blindness (and to death). Once patients entered a post-treatment health state 
they can progress to more severe health states, regress back to earlier stages of the 
disease, persist where they are, or die. NHS and personal social services perspec-
tive was adopted. Transition probabilities were based mainly on data derived from 
the Early Treatment Diabetic Retinopathy Study. Health state utilities, costs and 
complications were based on information from the literature, supplemented by 
expert opinion. Costs and outcomes were discounted at 3.5%. Both deterministic 
and probabilistic sensitivity analyses were conducted. Results: Administering 
panretinal photocoagulation at the severe NPDR stage was more effective and 
less costly than waiting until HR-PDR developed. Sensitivity analyses gave similar 
results, with early treatment continuing to dominate deferred treatment. The 
